The real divide this earnings season is runway: who sets the timeline, and who is set by it
Revenue growth, settlements and trial milestones all matter, but the Q3 filings show the balance sheet decides who can act on them at a time of their own choosing.
Same quarter, different freedoms
Read this batch of third-quarter results for what each company can do next, and the numbers sort into two groups. The first can choose its timing. The second has timing chosen for it.
Immunocore sits firmly in the first group. It reported $901 million in cash, cash equivalents and marketable securities at September 30. KIMMTRAK brought in $102.2 million in the quarter and $324.8 million over nine months, up 10% year to date. That is steady growth, not spectacular growth. The balance sheet is what lets Immunocore fund a Phase 3 melanoma trial that has completed enrollment of 540 patients, with overall survival topline expected in the second quarter of 2027. It can also plan a randomized Phase 2/3 in uveal melanoma and dose the first patient in a type 1 diabetes program. It can run all of this in parallel because no single readout has to rescue the company.
Talphera sits at the other end. It reported $14.2 million in cash and investments. Its news is substantive: the pivotal NEPHRO study exceeds 80% power for its primary endpoint, a briefing document is with FDA requesting an enrollment close based on patients enrolled as of December 31, and updated market research puts nafamostat peak sales in CRRT above $200 million. None of that is trivial. But a company with $14.2 million and a regulatory conversation still to resolve has little slack in its calendar. The commercial case is large relative to the cash, and the cash sets the pace.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Adjusted EBITDA is the headline number. This earnings season shows why the bridge matters more
Harrow, Liquidia and CorMedix each reported strong operating metrics beside very different GAAP and guidance pictures. Leaders should judge the bridge between those numbers, not the number on top.
Litigation is a launch cost, and earnings season is finally pricing it that way
Liquidia's $389.7 million settlement charge and Harrow's guidance reset show that the cost of defending a franchise belongs in the business case, not in a footnote below adjusted EBITDA.
A guidance raise is only as good as who controls the trigger
Q3 guidance moves look alike on a headline but differ in what they say about control. The companies that own their drivers have earned more trust than those waiting on a partner's calendar.